窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Caveolin 1 (CAV1) ,etc. by FLIA (Flow Luminescence Immunoassay)
VIP21; Caveolae Protein 22kDa
(注:?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) )
- 編號(hào)LMA214Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.01-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2427 ¥ 2521 ¥ 2661 ¥ 2847 ¥ 3034 ¥ 3314 ¥ 3734 計(jì)算器 ¥ 4668 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 88-99 | 93 |
EDTA plasma(n=5) | 87-104 | 93 |
heparin plasma(n=5) | 79-99 | 86 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-102% | 90-97% | 93-101% | 80-90% |
EDTA plasma(n=5) | 94-103% | 93-101% | 89-103% | 99-105% |
heparin plasma(n=5) | 78-104% | 78-103% | 99-105% | 88-96% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA214Mu01 | 窖蛋白(CAV1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA214Mu01 | 窖蛋白(CAV1)多克隆抗體 | WB; IHC; ICC; IP. |
SEA214Mu | 窖蛋白(CAV1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA214Mu | 窖蛋白(CAV1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Mendel Net | Novel prostate cancer tumour markers in a cell line model [Mendelu: source] |
Oncology reports | Caveolin-1 as a potential high-risk prostate cancer biomarker [PubMed: 22159333] |
Anticancer Research | Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men [Pubmed: 23645736] |
Sarcoidosis Vasc Diffuse Lung Dis.? | Decrased sputum caveolin-1 is associated with systemic sclerosis related lung disease [Pubmed:24751454] |
Cancer Genomics and Proteomics | Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression [PubMed: 26543085] |
Atherosclerosis | Genomic variant in CAV1 increases susceptibility to coronary artery disease and myocardial infarction [Pubmed:26775120] |
Arthritis Research & Therapy | Increased caveolin-1 in intervertebral disc degeneration facilitates repair [Pubmed:26939667] |
Oxid Med Cell Longev | Lower Serum Caveolin-1 Is Associated with Cerebral Microbleeds in Patients with Acute Ischemic Stroke [Pubmed:27119011] |
Inflammation | Caveolin-1?Promotes?the?Imbalance?of?Th17/Treg?in?Patients?with?Chronic?Obstructive?PulmonaryDisease. [pubmed:27613621] |
Oxidative Medicine and Cellular Longevity | Swim Training Modulates Skeletal Muscle Energy Metabolism, Oxidative Stress, and Mitochondrial Cholesterol Content in Amyotrophic Lateral Sclerosis Mice [Pubmed:29849903] |
Microcirculation | Endothelium‐dependent hyperpolarization‐mediated vasodilatation compensates nitric oxide‐mediated endothelial dysfunction during ischemia in diabetes‐induced?… [Pubmed:29665152] |
Genetic Testing and Molecular Biomarkers | The CAV1 Gene 3′ Untranslated Region Single Nucleotide Polymorphisms Are Associated with the Risk of Pulmonary Hypertension in Chinese Han Chronic?… [] |
Cell Rep | SIRT6 transcriptionally regulates fatty acid transport by suppressing PPAR|? [34077730] |
researchsquare | Cav-1 Protein Levels in Serum and Infarcted Brain Correlate with Hemorrhagic Volume in a Mouse Model of Thromboembolic Stroke, Independently of Rt-PA??- [] |
Molecules | 5, 2′-Dibromo-2, 4′, 5′-trihydroxydiphenylmethanone Inhibits LPS-Induced Vascular Inflammation by Targeting the Cav1 Protein [Pubmed:35566232] |